{
  "id": 17249540,
  "title": "No Nonsense: David Liu Lauds Progress in Disease-Agnostic Gene Editing at ESGCT",
  "url": "https://urgent.news/2026/10/30/no-nonsense-david-liu-lauds-progress-in-disease-agnostic-gene-editing",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-30T15:38:49.000Z",
  "source": {
    "name": "GEN Biotechnology",
    "slug": "gen-biotechnology",
    "url": "https://www.genengnews.com/topics/genome-editing/no-nonsense-david-liu-lauds-progress-in-disease-agnostic-gene-editing-at-esgct/"
  },
  "original_language": "en",
  "account": "Hamburg — Pre-eminent researcher David Liu, PhD, opened his plenary session at the European Society of Gene & Cell Therapy (ESGCT) 2026 by acknowledging fellow speaker and 2018 Kavli Award winner Virginijus Siksnys, PhD, jokingly referring to himself as \"just the warm up.\" Liu highlighted the significance of recent advancements in therapeutic genome editing, noting the convergence of scientific approaches, regulatory, manufacturing, and economic progress to advance the mission of expanding genome editing beyond genetic diseases affecting approximately 400 million families globally.\n\nLiu's journey into precision genome editing began ten years ago with the publication of the first base editing report, followed by the description of prime editing three years later. Both building on the CRISPR-Cas platform, these technologies offer a broad range of potential gene edits, including single-base substitutions, with commercial applications spearheaded by Liu's companies Beam Therapeutics and Prime Medicine. Liu showcased how his lab leverages AI in prime editing development, notably the use of ProteinMPNN, an AI tool that aids in generating stable prime editors, and OptiPrime, a machine learning tool for predicting prime editing outcomes. He also discussed the evolution of prime editors via phage-assisted continuous evolution (PACE) and the development of free machine learning tool OptiPrime to streamline pegRNA selection for enhanced editing efficiency.\n\nReflecting on the rapid progression of disease phenotypes rescue in animal models, Liu cited examples ranging from progeria to spinal muscular atrophy, many of which have entered IND-enabled studies and are showing promising clinical results. Recent milestones include Beam Therapeutics' first clinical correction of a human pathogenic mutation in alpha-1 antitrypsin deficiency and the successful prime editing of stem cells for Wilson disease, marking significant steps forward in clinical application. Liu expressed optimism about regulatory liberalization in major jurisdictions, citing the recent FDA draft guidance on individualized human genome editing products, which he believes signifies a positive shift in policy support for groundbreaking therapies.",
  "summary": "Liu ensured that his return visit to ESGCT (having spoken at the congress in Barcelona in 2019) would be one of the highlights of the conference. The “meta lesson” of the past few years in therapeutic genome editing is that different scientific approaches and applications can synergize with regulatory, manufacturing, and economic advances “to achieve the mission we’re on.” The post No Nonsense:…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}